BR112019011450A2 - células naturais killer modificadas e uso das mesmas - Google Patents

células naturais killer modificadas e uso das mesmas

Info

Publication number
BR112019011450A2
BR112019011450A2 BR112019011450A BR112019011450A BR112019011450A2 BR 112019011450 A2 BR112019011450 A2 BR 112019011450A2 BR 112019011450 A BR112019011450 A BR 112019011450A BR 112019011450 A BR112019011450 A BR 112019011450A BR 112019011450 A2 BR112019011450 A2 BR 112019011450A2
Authority
BR
Brazil
Prior art keywords
natural killer
killer cells
modified natural
modified
cells
Prior art date
Application number
BR112019011450A
Other languages
English (en)
Inventor
Eamon Peter O'dwyer Michael
Original Assignee
Onkimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60937693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019011450(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onkimmune Ltd filed Critical Onkimmune Ltd
Publication of BR112019011450A2 publication Critical patent/BR112019011450A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001126—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464426—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

são fornecidas na presente invenção células naturais killer modificadas que foram modificadas para expressar receptores de antígenos quiméricos (cars). as células contém, opcionalmente, outras modificações que melhoram a citotoxicidade específica do tumor e retorno para locais de tumor. também são contemplados métodos para usar as células naturais killer modificadas para tratar pacientes com câncer.
BR112019011450A 2016-12-09 2017-12-11 células naturais killer modificadas e uso das mesmas BR112019011450A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662432302P 2016-12-09 2016-12-09
PCT/EP2017/082292 WO2018104562A1 (en) 2016-12-09 2017-12-11 Engineered natural killer cells and uses thereof

Publications (1)

Publication Number Publication Date
BR112019011450A2 true BR112019011450A2 (pt) 2019-10-15

Family

ID=60937693

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019011450A BR112019011450A2 (pt) 2016-12-09 2017-12-11 células naturais killer modificadas e uso das mesmas

Country Status (12)

Country Link
US (2) US10799536B2 (pt)
EP (4) EP3895712B1 (pt)
JP (2) JP7228900B2 (pt)
KR (1) KR20190114966A (pt)
CN (2) CN117305250A (pt)
AU (1) AU2017371517B2 (pt)
BR (1) BR112019011450A2 (pt)
CA (1) CA3045386A1 (pt)
DK (2) DK3581190T3 (pt)
ES (3) ES2875005T3 (pt)
MX (1) MX2019006598A (pt)
WO (1) WO2018104562A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
CN117305250A (zh) * 2016-12-09 2023-12-29 昂克医疗有限公司 工程化天然杀伤细胞及其用途
AU2019271366A1 (en) * 2018-05-16 2021-01-14 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins
US10960024B2 (en) * 2018-08-01 2021-03-30 Nantkwest, Inc. Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
EP3843750A4 (en) * 2018-08-29 2022-05-25 Academia Sinica COMBINATION OF NATURAL KILLER CELLS WITH CYCLOPHOSPHAMIDE COMPOUNDS FOR THE TREATMENT OF CANCER
KR102292657B1 (ko) 2019-03-15 2021-08-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
WO2020189942A1 (ko) * 2019-03-15 2020-09-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
EP3958875A4 (en) * 2019-04-25 2023-05-10 Purdue Research Foundation GENETICALLY MODIFIED NATURAL KILLER CELLS REDIRECTED TO PURINERGIC SIGNALING, THEIR CONSTRUCTIONS AND METHODS OF USE
BR112022008215A2 (pt) * 2019-10-31 2022-07-12 Res Inst Nationwide Childrens Hospital Geração de células nk humanas primárias e expandidas knock-out de cd38
US20230036481A1 (en) * 2020-01-16 2023-02-02 Acepodia Biotechnologies Ltd. A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell
WO2021209625A1 (en) * 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells
US20240141295A1 (en) 2020-08-31 2024-05-02 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
CN114426583B (zh) * 2020-10-29 2023-10-10 中国科学技术大学 用于急性髓系白血病的细胞疗法的嵌合抗原受体
KR20220091426A (ko) 2020-12-23 2022-06-30 주식회사 휴먼셀바이오 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물
EP4355860A1 (en) 2021-06-18 2024-04-24 ONK Therapeutics Limited Double knockout natural killer cells
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
CA3231204A1 (en) * 2021-09-18 2023-03-23 Feng Wang-Johanning Herv-k antibody, cell, vaccine, and drug therapeutics
WO2023102201A2 (en) * 2021-12-03 2023-06-08 University Of Utah Research Foundation High selective cd229 antigen binding domains and methods of use
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
EP4353741A1 (en) 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
WO2024100203A1 (en) 2022-11-10 2024-05-16 Onk Therapeutics Limited Combined therapies using immunomodulating drugs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520459A (ja) * 2003-02-14 2009-05-28 サイグレス ディスカバリー， インコーポレイテッド 癌における治療標的
CN101218256B (zh) 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US9040050B2 (en) 2006-09-26 2015-05-26 Genmab A/S Combination treatment of CD38-expressing tumors
CA2667067A1 (en) 2006-10-19 2008-04-24 Merck & Co., Inc. Antibody antagonists of interleukin-13 receptor .alpha.1
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
EP3456818B1 (en) 2013-03-07 2020-05-20 Baylor College of Medicine Targeting cd138 in cancer
EP3104866A4 (en) * 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP3505623A1 (en) * 2014-02-14 2019-07-03 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
DK3237436T3 (da) 2014-12-24 2019-08-12 Aadigen Llc Peptider og nanopartikler til intracellulær indgivelse af molekyler
US20180021378A1 (en) 2014-12-31 2018-01-25 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
AU2016277121C1 (en) 2015-06-12 2022-07-14 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
JP6974681B2 (ja) 2015-07-29 2021-12-01 オーエヌケー セラピューティクス リミテッド 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN117305250A (zh) 2016-12-09 2023-12-29 昂克医疗有限公司 工程化天然杀伤细胞及其用途

Also Published As

Publication number Publication date
AU2017371517B2 (en) 2023-01-05
US10799536B2 (en) 2020-10-13
MX2019006598A (es) 2019-10-15
EP3895712A1 (en) 2021-10-20
AU2017371517A1 (en) 2019-07-04
EP3581190B1 (en) 2021-03-10
EP3454871A1 (en) 2019-03-20
RU2019121509A (ru) 2021-01-11
CN110248669B (zh) 2023-09-08
RU2019121509A3 (pt) 2021-03-30
KR20190114966A (ko) 2019-10-10
EP3454871B1 (en) 2019-06-26
JP2023052980A (ja) 2023-04-12
EP4104841A1 (en) 2022-12-21
DK3454871T3 (da) 2019-09-16
US20180161371A1 (en) 2018-06-14
EP3581190A1 (en) 2019-12-18
CN117305250A (zh) 2023-12-29
US20210046118A1 (en) 2021-02-18
ES2746856T3 (es) 2020-03-09
JP7228900B2 (ja) 2023-02-27
WO2018104562A1 (en) 2018-06-14
CA3045386A1 (en) 2018-06-14
JP2020503891A (ja) 2020-02-06
DK3581190T3 (da) 2021-06-07
EP3895712B1 (en) 2022-06-22
ES2926397T3 (es) 2022-10-26
ES2875005T3 (es) 2021-11-08
CN110248669A (zh) 2019-09-17

Similar Documents

Publication Publication Date Title
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2020006668A (es) Anticuerpos para lilrb2.
CO2017010502A2 (es) Receptores del antígeno quimérico dirigidos al antígeno de maduración de células b
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
ECSP17027870A (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer
CR20170079A (es) Agentes de unión a cd123 y usos de estos
BR112018073574A2 (pt) conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização
CL2020000233A1 (es) Anticuerpos anti-cd137.
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CO7160093A2 (es) Anticuerpos anti-egfr y usos de los mismos
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CL2020002446A1 (es) Anticuerpos contra mica y/o micb y sus usos
CR20110553A (es) Terapia complementaria contra el cáncer
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CL2016002245A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
PE20160528A1 (es) Anticuerpos
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
BR112022000120A2 (pt) Projeto e sínteses eficientes de conjugados de lipídeo-fluoresceína para terapia de células car-t
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ONK THERAPEUTICS LIMITED (IE)

B25G Requested change of headquarter approved

Owner name: ONK THERAPEUTICS LIMITED (IE)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]